2023 World Conference on Lung Cancer (Posters)-P1.03. Combinationof Anlotinib and Tislelizumab for Lung Adenocarcinoma: Effects on Metabolic and Flora Microenvironment

P1.03. Combinationof Anlotinib and Tislelizumab for Lung Adenocarcinoma: Effects on Metabolic and Flora Microenvironment - PDF(Abstract)

Back to course

Pdf Summary

This study explores the effects of combining the antiangiogenic drug Anlotinib and the immunotherapy drug Tislelizumab for lung adenocarcinoma. The researchers aimed to understand the specific molecular mechanisms behind this combination therapy by studying immune cells, cytokines, intestinal flora, metabolomics, and transcriptomics.<br /><br />Using a mouse model of lung cancer, the researchers observed that the combination treatment group showed the slowest tumor growth. They also found that the levels of IL-2 and IFN-γ, as well as the number of CD4 and CD8 T cells in tumor tissues, were increased in the combination treatment group compared to the monotherapy groups. Additionally, the expression levels of VEGF, CD31, CD34, and MVD were lower in the combination treatment group than in the tislelizumab monotherapy group, suggesting inhibition of neovascularization.<br /><br />The researchers also analyzed the effects of combination therapy on the intestinal flora and metabolites. They found that the microbial diversity and richness of the intestinal microbiota decreased in the combination treatment group. Specific flora such as Rikenellaceae, Verrucomicobia, Verrucomicrobiaceae, and Akkermansia increased in the combination therapy group, indicating changes in the intestinal microbial environment. Furthermore, several metabolites in the intestinal tissues of mice in the combination group were expressed differently, and key metabolic markers and pathways related to glucose metabolism, vitamin absorption, and mTOR signaling were identified.<br /><br />RNA sequencing analysis revealed key genes and signaling pathways associated with the combination therapy's anti-tumor effects. The study also found that the higher expression level of the Plaur gene weakened its tumor suppressive effect.<br /><br />In conclusion, the combination therapy of Anlotinib and Tislelizumab effectively activated immune cells, inhibited neovascularization, and caused changes in intestinal flora and metabolites in the mouse model. The study identified genes and signaling pathways related to the combination therapy, which could potentially inform personalized and comprehensive treatment approaches in clinical settings.

Asset Subtitle

Yuanliu Nie

Meta Tag

Speaker Yuanliu Nie

Topic Tumor Biology: Preclinical Biology - Omics Approaches

Keywords

Anlotinib

Tislelizumab

lung adenocarcinoma

combination therapy

immune cells

neovascularization

intestinal flora

metabolites

signaling pathways

tumor suppressive effect